For patients with advanced leukemia, access to high-quality end-of-life care appears to be reduced in those dependent on blood transfusions, according to a new study being presented during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta. The study associates this reduced access and consequent diminished use of hospice services with a reduced quality of end-of-life care for these patients.
In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the US FDA found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th ASH Annual Meeting and Exposition in Atlanta.
Survivorship care plan improves patient cancer care-related distress levels for hematopoietic cell transplant recipients. Results from a recent multicenter study presented at the American Society of Hematology (ASH) Annual Meeting.
For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta spotlight the emerging role played by chimeric antigen receptor (CAR) T-cell therapies in helping individuals mount a clinical response and, in some cases, achieve durable remission.
Gene editing has begun to be tested in clinical trials, using CRISPR-Cas9 and other technologies to directly edit DNA inside people's cells, and multiple trials are recruiting or in planning. A new study raises a note of caution, finding person-to-person genetic differences that may undercut the efficacy of gene editing or, more rarely, cause potentially dangerous 'off target' effects. It suggests that gene editing may need to be adapted to each patient's genome.
As previously informed, the Phase III trial, ADMYRE, which compared plitidepsin in combination with dexamethasone versus dexamethasone alone met its primary endpoint, progression free survival, and secondary objectives, overall survival and safety
In four studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers announce promising findings on innovative tools and therapies for hard-to-treat blood disorders including sickle cell disease (SCD), beta thalassemia, and X-linked severe combined immunodeficiency (X-SCID). The studies employ unique therapeutic approaches and advanced engineering technologies such as the gene-editing platform CRISPR/Cas9, reflecting the fruits of many years of research dedication and innovation.
In three studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report remarkable benefits from new, more easily administered therapies for bleeding and clotting disorders, including hemophilia A and people with cancer experiencing venous thromboembolism.
Azacitidine reverses resistance to SL-401 in AML and BPDCN cell lines, researchers find. Results prompt clinical trial of SL-401 and azacitidine in AML and MDS patients.
Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.